U.K. firm Kontron goes into receivership

Article

U.K. ultrasound and patient monitoring firm Kontron Instruments has gone into receivership, according to the administrator of its accounts, international accounting firm KPMG. KPMG attributed the company's failure to the reduction in healthcare spending

U.K. ultrasound and patient monitoring firm Kontron Instruments has gone into receivership, according to the administrator of its accounts, international accounting firm KPMG. KPMG attributed the company's failure to the reduction in healthcare spending in Europe, 1998's downturn in the Asian market, and increased competition in the overall healthcare market. Watford, U.K.-based Kontron reported revenues of about $24 million for the 12 months ended June 30, 1997.

The company's assets include intellectual property rights to its monitoring products, an electronic assembly plant and its machinery, raw materials, and stock. KPMG seeks to sell Kontron as a going concern and expects to find a buyer shortly, according to Paul Jeffery, administrative receiver for KPMG in Hertfordshire, U.K. Kontron owes roughly $8 million to its 450 creditors.

Recent Videos
New Mammography Studies Assess Image-Based AI Risk Models and Breast Arterial Calcification Detection
Can Deep Learning Provide a CT-Less Alternative for Attenuation Compensation with SPECT MPI?
Employing AI in Detecting Subdural Hematomas on Head CTs: An Interview with Jeremy Heit, MD, PhD
Pertinent Insights into the Imaging of Patients with Marfan Syndrome
What New Brain MRI Research Reveals About Cannabis Use and Working Memory Tasks
Current and Emerging Legislative Priorities for Radiology in 2025
How Will the New FDA Guidance Affect AI Software in Radiology?: An Interview with Nina Kottler, MD, Part 2
A Closer Look at the New Appropriate Use Criteria for Brain PET: An Interview with Phillip Kuo, MD, Part 2
How Will the New FDA Guidance Affect AI Software in Radiology?: An Interview with Nina Kottler, MD, Part 1
A Closer Look at the New Appropriate Use Criteria for Brain PET: An Interview with Phillip Kuo, MD, Part 1
Related Content
© 2025 MJH Life Sciences

All rights reserved.